ICG Fluorescence Imaging in Trauma Patients

Status Completed

Clinical Trial Summary

Clinical Trial Description

This will be a prospective observational trial to better understand the range and variation associated with bone/soft tissue perfusion in fracture patients and examine the relationship between perfusion, measured using quantitative Indocyanine green (ICG) fluorescence and complications such as surgical site infection (SSI), persistent SSI, and fracture nonunion. Primary outcome measure is complication (either infection, recurrent infection or nonunion). Eligible consenting patients will receive standard of care treatment for their fracture or infection including irrigation and debridement of their operative site and/or fracture fixation. After exposure, 0.1 mg/Kg ICG will be injected intravenously and video rate ICG fluorescence images will be acquired 20 seconds before and 4 minutes after the injection, each before and after debridement. A subset of 38 post-fracture complication patients will undergo surgical treatment for their infection in Center of Innovation Surgery (CIS) and have either an intraoperative Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) after exposure but before the ICG injection or a preoperative DCE-MRI. Patients receiving surgery in the CIS will be required to sign an additional CIS-specific consent document. The need for repeat surgical procedure will be left up to the treating surgeon. If repeat procedure is needed, pre- and post-debridement quantitative ICG fluorescence images will be obtained at each procedure. Study participants will be followed at 2 weeks, 6 weeks, 3 months and 6 months from their index study surgery. Complication including index infection, recurrent infection or delaying union/nonunion will be identified at the time of diagnosis and/or during each participants assessment that occurs during routine outpatient clinic visit. Detailed information on the infection including date of diagnosis, participant signs and symptoms, culture test results, method of treatment(s), and date of resolution will be documented. 4/23/2020: Study recruitment temporarily halted due to COVID-19 ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04245111
Study type	Observational [Patient Registry]
Source	Dartmouth-Hitchcock Medical Center
Contact
Status	Completed
Phase
Start date	May 16, 2019
Completion date	November 18, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04567901` - GNRI and Influence of Nutrition on the Mortality of Trauma Patients
Enrolling by invitation	`NCT05794165` - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism	Phase 2
Not yet recruiting	`NCT06326827` - In'Oss™ (MBCP® Putty) Ortho
Recruiting	`NCT04403204` - ICG Fluorescence Imaging in Post-traumatic Infection
Completed	`NCT04913402` - Sufentanil Used by Paramedics to Treat Pain in Acute Trauma
Not yet recruiting	`NCT06070350` - Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children	Phase 3
Recruiting	`NCT05616130` - Pathological Myeloid Activation After Sepsis and Trauma
Completed	`NCT05628519` - Captain Sonar Impact on Trauma Patient Management	N/A
Recruiting	`NCT04907240` - Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
Recruiting	`NCT06123104` - Assessment of Automatic Tourniquets for Soldiers During Wartime	N/A
Recruiting	`NCT05865327` - UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture	N/A
Completed	`NCT05175872` - Factors Affecting Mortality and Morbidity in Trauma Patients Followed in Intensive Care Unit
Not yet recruiting	`NCT04387305` - Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study	Phase 3
Recruiting	`NCT04416412` - ICG Fluorescence Imaging in Open Fracture Trauma Patients
Completed	`NCT04080479` - Bolus Versus Continuous Enteral Tube Feeding	N/A
Completed	`NCT04030832` - Reconstruction of Skin Substance Loss With "Micro-grafts" Obtained by Mechanical Disintegration
Active, not recruiting	`NCT06063434` - Testing the Effectiveness of Night Shift, a Theory-based Customized Video Game	N/A
Not yet recruiting	`NCT04954768` - Epidemiological Characteristics of Elderly Trauma Patients in Zhejiang Province and Development of Geriatric Trauma Short-term Mortality Prediction Model
Completed	`NCT04327895` - Surgery in Context of Terrorist Attack : a Survey of French Surgeons
Completed	`NCT03888703` - The Use of Fractional Ablative CO2 Laser vs Control on Acute Traumatic Injuries to Prevent Scar Formation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.